CCDC12 gene methylation in peripheral blood as a potential biomarker for breast cancer detection.

IF 2 4区医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Biomarkers Pub Date : 2024-07-01 Epub Date: 2024-06-07 DOI:10.1080/1354750X.2024.2358302

Jingjing Liu, Yunhui Qu, Yutong Zhao, Feifei Liang, Longtao Ji, Zhi Wang, Jinyu Li, Zishan Zang, Haixia Huang, Jie Zhang, Wanjian Gu, Liping Dai, Rongxi Yang

{"title":"CCDC12 gene methylation in peripheral blood as a potential biomarker for breast cancer detection.","authors":"Jingjing Liu, Yunhui Qu, Yutong Zhao, Feifei Liang, Longtao Ji, Zhi Wang, Jinyu Li, Zishan Zang, Haixia Huang, Jie Zhang, Wanjian Gu, Liping Dai, Rongxi Yang","doi":"10.1080/1354750X.2024.2358302","DOIUrl":null,"url":null,"abstract":"Background: Aberrant DNA methylation has been identified as biomarkers for breast cancer detection. Coiled-coil domain containing 12 gene (CCDC12) implicated in tumorigenesis. This study aims to investigate the potential of blood-based CCDC12 methylation for breast cancer detection.Methods: DNA methylation level of CpG sites (Cytosine-phosphate Guanine dinucleotides) in CCDC12 gene was measured by mass spectrometry in 255 breast cancer patients, 155 patients with benign breast nodules and 302 healthy controls. The association between CCDC12 methylation and breast cancer risk was evaluated by logistic regression and receiver operating characteristic curve analysis.Results: A total of eleven CpG sites were analyzed. The CCDC12 methylation levels were higher in breast cancer patients. Compared to the lowest tertile of methylation level in CpG_6,7, CpG_10 and CpG_11, the highest quartile was associated with 82, 91 and 95% increased breast cancer risk, respectively. The CCDC12 methylation levels were associated with estrogen receptor (ER) and human epidermal growth factor 2 (HER2) status. In ER-negative and HER2-positive (ER-/HER2+) breast cancer subtype, the combination of four sites CpG_2, CpG_5, CpG_6,7 and CpG_11 methylation levels could distinguish ER-/HER2+ breast cancer from the controls (AUC = 0.727).Conclusion: The hypermethylation levels of CCDC12 in peripheral blood could be used for breast cancer detection.","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1354750X.2024.2358302","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/7 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Aberrant DNA methylation has been identified as biomarkers for breast cancer detection. Coiled-coil domain containing 12 gene (CCDC12) implicated in tumorigenesis. This study aims to investigate the potential of blood-based CCDC12 methylation for breast cancer detection.

Methods: DNA methylation level of CpG sites (Cytosine-phosphate Guanine dinucleotides) in CCDC12 gene was measured by mass spectrometry in 255 breast cancer patients, 155 patients with benign breast nodules and 302 healthy controls. The association between CCDC12 methylation and breast cancer risk was evaluated by logistic regression and receiver operating characteristic curve analysis.

Results: A total of eleven CpG sites were analyzed. The CCDC12 methylation levels were higher in breast cancer patients. Compared to the lowest tertile of methylation level in CpG_6,7, CpG_10 and CpG_11, the highest quartile was associated with 82, 91 and 95% increased breast cancer risk, respectively. The CCDC12 methylation levels were associated with estrogen receptor (ER) and human epidermal growth factor 2 (HER2) status. In ER-negative and HER2-positive (ER-/HER2+) breast cancer subtype, the combination of four sites CpG_2, CpG_5, CpG_6,7 and CpG_11 methylation levels could distinguish ER-/HER2+ breast cancer from the controls (AUC = 0.727).

Conclusion: The hypermethylation levels of CCDC12 in peripheral blood could be used for breast cancer detection.

查看原文本刊更多论文

外周血中的 CCDC12 基因甲基化是检测乳腺癌的潜在生物标志物。

背景：DNA甲基化异常已被确定为检测乳腺癌的生物标志物。含有盘绕线圈结构域的 12 基因（CCDC12）与肿瘤发生有关。本研究旨在探讨基于血液的 CCDC12 甲基化检测乳腺癌的潜力：方法：采用质谱法测量了 255 名乳腺癌患者、155 名良性乳腺结节患者和 302 名健康对照者 CCDC12 基因中 CpG 位点（胞嘧啶-磷酸鸟嘌呤二核苷酸）的 DNA 甲基化水平。通过逻辑回归和接收器操作特征曲线分析评估了 CCDC12 基因甲基化与乳腺癌风险之间的关系：结果：共分析了 11 个 CpG 位点。乳腺癌患者的 CCDC12 甲基化水平较高。与 CpG_6、7、CpG_10 和 CpG_11 的甲基化水平最低四分位数相比，最高四分位数分别与 82%、91% 和 95% 的乳腺癌风险增加相关。CCDC12 甲基化水平与雌激素受体（ER）和人类表皮生长因子 2（HER2）状态有关。在ER阴性和HER2阳性（ER-/HER2+）乳腺癌亚型中，CpG_2、CpG_5、CpG_6、7和CpG_11四个位点甲基化水平的组合可将ER-/HER2+乳腺癌与对照组区分开来（AUC = 0.727）：结论：外周血中 CCDC12 的高甲基化水平可用于乳腺癌检测。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers 医学-毒理学

CiteScore

5.00

自引率

3.80%

发文量

140

审稿时长

3 months

期刊介绍： The journal Biomarkers brings together all aspects of the rapidly growing field of biomarker research, encompassing their various uses and applications in one essential source. Biomarkers provides a vital forum for the exchange of ideas and concepts in all areas of biomarker research. High quality papers in four main areas are accepted and manuscripts describing novel biomarkers and their subsequent validation are especially encouraged: • Biomarkers of disease • Biomarkers of exposure • Biomarkers of response • Biomarkers of susceptibility Manuscripts can describe biomarkers measured in humans or other animals in vivo or in vitro. Biomarkers will consider publishing negative data from studies of biomarkers of susceptibility in human populations.